{
    "2019-07-02": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Is AbbVie a Buy?",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Buy"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-03-15",
                "original_text": "Why This Gilead-AbbVie Rivalry Could Come To A Head In 2020",
                "features": {
                    "keywords": [
                        "Gilead",
                        "AbbVie",
                        "rivalry"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-07-20",
                "original_text": "IBM Is Set to Join Exclusive Group of Dividend Aristocrats",
                "features": {
                    "keywords": [
                        "IBM",
                        "Dividend Aristocrats"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "technology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-11-10",
                "original_text": "Gilead to Submit NDA for Inflammation Drug Filgotinib in '19",
                "features": {
                    "keywords": [
                        "Gilead",
                        "NDA",
                        "Filgotinib"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-12-05",
                "original_text": "Insiders Buy the Holdings of DLN ETF",
                "features": {
                    "keywords": [
                        "Insiders",
                        "DLN ETF"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-12-15",
                "original_text": "3 Biotechs That Have Doubled This Year (Acquisition Next?)",
                "features": {
                    "keywords": [
                        "Biotechs",
                        "Acquisition"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-12-20",
                "original_text": "AbbVieâ€™s Allergan Acquisition Sowed Doubts on Wall Street. Some Analysts Are Coming Around.",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Allergan",
                        "Acquisition"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-01-05",
                "original_text": "Gilead Surges in the Race for Next Big Anti-Inflammatory Drug",
                "features": {
                    "keywords": [
                        "Gilead",
                        "Anti-Inflammatory Drug"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-01-10",
                "original_text": "Patent panic gives green light to mega pharma deals",
                "features": {
                    "keywords": [
                        "Patent panic",
                        "mega pharma deals"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}